Your browser is no longer supported. Please, upgrade your browser.
Settings
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)- Insider Own1.18% Shs Outstand238.67M Perf Week1.52%
Market Cap24.88B Forward P/E5.96 EPS next Y17.84 Insider Trans0.00% Shs Float223.06M Perf Month6.23%
Income- PEG- EPS next Q0.17 Inst Own10.60% Short Float2.64% Perf Quarter19.84%
Sales- P/S- EPS this Y-300.50% Inst Trans0.90% Short Ratio1.44 Perf Half Y22.84%
Book/sh4.73 P/B22.47 EPS next Y1275.00% ROA- Target Price118.66 Perf Year220.15%
Cash/sh5.24 P/C20.29 EPS next 5Y- ROE- 52W Range28.00 - 131.00 Perf YTD30.39%
Dividend- P/FCF- EPS past 5Y- ROI-31.40% 52W High-18.86% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low279.61% ATR5.97
Employees1800 Current Ratio4.10 Sales Q/Q-47.10% Oper. Margin- RSI (14)53.70 Volatility4.72% 5.68%
OptionableYes Debt/Eq0.34 EPS Q/Q-314.60% Profit Margin- Rel Volume0.95 Prev Close110.61
ShortableYes LT Debt/Eq0.19 EarningsNov 10 BMO Payout- Avg Volume4.09M Price106.29
Recom2.20 SMA208.83% SMA501.50% SMA20039.59% Volume3,863,894 Change-3.91%
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
Jan-27-21 07:51AM  
07:00AM  
05:49AM  
05:02AM  
02:00AM  
01:35AM  
Jan-26-21 01:35PM  
12:59PM  
12:39PM  
11:28AM  
10:10AM  
09:40AM  
08:19AM  
07:06AM  
Jan-25-21 05:46PM  
04:38PM  
04:36PM  
12:37PM  
12:20PM  
12:18PM  
11:41AM  
11:21AM  
10:31AM  
09:00AM  
08:24AM  
07:58AM  
04:42AM  
01:57AM  
Jan-24-21 05:01PM  
08:15AM  
Jan-23-21 03:29PM  
10:30AM  
06:44AM  
06:04AM  
Jan-22-21 04:08PM  
02:55PM  
12:15PM  
12:00PM  
09:36AM  
08:06AM  
08:00AM  
07:00AM  
Jan-21-21 07:15PM  
04:27PM  
10:11AM  
09:58AM  
04:44AM  
Jan-20-21 04:13PM  
03:05PM  
10:46AM  
07:50AM  
07:48AM  
Jan-19-21 01:15PM  
07:46AM  
Jan-18-21 11:34AM  
08:46AM  
Jan-17-21 07:02AM  
Jan-16-21 02:55AM  
Jan-15-21 01:46PM  
10:55AM  
10:11AM  
09:43AM  
Jan-14-21 04:55PM  
03:31PM  
06:41AM  
Jan-13-21 05:44PM  
01:02PM  
12:48PM  
05:45AM  
Jan-12-21 11:05PM  
04:29PM  
01:16PM  
01:02PM  
11:03AM  
10:37AM  
10:22AM  
09:57AM  
09:18AM  
08:16AM  
08:00AM  
06:05AM  
Jan-11-21 06:04PM  
04:34PM  
02:03PM  
12:29PM  
01:00AM  
Jan-10-21 11:25PM  
07:00AM  
Jan-09-21 01:00AM  
Jan-08-21 04:32PM  
03:37PM  
03:14PM  
01:23PM  
12:59PM  
12:29PM  
10:55AM  
10:41AM  
10:00AM  
09:47AM  
09:00AM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.